Many babies should get a shot soon after birth to protect them from RSV, or respiratory syncytial virus, a panel of the Centers for Disease Control and Prevention’s outside advisers voted Thursday. The recommendation clears the way for a new option experts have hailed as a historic advance to curb thefor American infants.
The panel voted unanimously to endorse giving Sanofi and AstraZeneca’s nirsevimab antibody drug, branded as Beyfortus, to protect babies born into the colder months — October through March — when RSV infections typically climb in much of the country.
Some babies who are at increased risk of severe RSV disease will also be recommended to get another dose during their second RSV season.
“I would be remiss if I didn’t say that today is a historic event. I think that we will look back on this, in a short period of time, and see what a major impact this vote has had on the health and wellbeing of children in the United States. I think that this will mark one of the major accomplishments of the ACIP,” Dr. José Romero, MD, director of the National Center for Immunization and Respiratory Diseases, said in closing the meeting.
Beyfortus wasby the Food and Drug Administration in July, after results showed a steep reduction in hospitalizations from RSV after infants got the antibody injection. Data suggests the protection could last for at least 5 months.
While virtually all children catch RSV within their first few years of life, the virus poses a higher risk of hospitalization for babies who catch it during their earliest months of life.
CDC survey results presented to the committee suggest 70% of parents were open to getting their newborns the antibody injections to avoid RSV.
Unlike a traditional vaccine, which works to train the body’s own immune defenses against the virus, a shot of the antibody drug works to directly fend off the virus in the body.
It is part of a growing roster of “long-acting” passive immunizations that can quickly offer months of protection against diseases — a key asset for babies who might be exposed to RSV during their most vulnerable first months of life.
“Thanks to advances in biotechnology, we now have the opportunity to prevent infectious diseases with long-acting monoclonal antibodies. When used for passive immunization, these products can provide a level of protection similar to see to that we see with traditional vaccine, but for a limited period of time,” the CDC’s Dr. Melinda Wharton told the panel.
This technicality has posed months of logistical challenges for public health authorities, officials outlined for the committee, as they have worked to adapt policies and systems designed for “vaccines” to cover the new antibody drug.
Similar to other shots, the CDC plans to monitor how well Beyfortus is working in the real world through its ongoing vaccine effectiveness studies. The agency has also drawn up plans to monitor reports of safety issues, as well as tracking the possibility RSV might evolve resistance.
The panel from also voted Thursday to back including Beyfortus in the federal Vaccines for Children program, guaranteeing broad access to the shots for underinsured children.
Beyfortus is also pricier than many other vaccines. Sanofi says the list price of the drug could run as much as $495 before insurance, officials said, with a discounted price of $395 for the the Vaccines for Children program. The hepatitis B vaccine, which is also given to newborns, costs less than $20 per dose.